Evidence map›Paper›PMID 37932468›Full record

ArticleAnnals of hematology2024

CEAC (oral semustine, etoposide, cytarabine and cyclophosphamide) vs BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning regimen of autologous stem cell transplantation for diffuse large B-cell lymphoma: a post-hoc, propensity score-matched, cohort study in Chinese patients.

Tao Wang, Ping Liu, Lili Xu, Lei Gao, Xiong Ni, Gusheng Tang, Li Chen, Jie Chen, Libing Wang, Yang Wang and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Tao Wang *Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Ping Liu *Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Lili XuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Lei GaoDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Xiong NiDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Gusheng TangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Li ChenDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Jie ChenDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Libing WangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Yang WangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Weijia FuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Wenqin YueDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Na LiuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Ruobing LiDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Guihua LuDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. lovelugh@163.com.
Yanrong LuoDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. 122158553@qq.com.
Jianmin YangDepartment of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China. chyangjianmin@163.com.ORCID http://orcid.org/0000-0002-1789-9767
Second Military Medical University · CN

Funding

National Natural Science Foundation of China 82270202Science and Technology Commission of Shanghai Municipality 23YF1458800
6 · The paper itself

Abstract

Autologous stem cell transplantation (ASCT) is a salvage therapy for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). We have developed a novel conditioning regimen called CEAC (oral semustine 250 mg/m

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsCarmustineCohort StudiesCyclophosphamideCytarabineEtoposideHumansMelphalanNeoplasm Recurrence, LocalPropensity ScoreSemustineTransplantation, AutologousCarmustineCyclophosphamideCytarabineEtoposideMelphalanSemustineAutologous stem cell transplantationBEAM regimenCEAC regimenConditioning therapyDiffuse large B-cell lymphoma

Identifiers

PMID37932468
OpenAlexW4388407446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.